PharmiWeb

Multiple System Atrophy Therapeutics Market Growth Outlook to 2033: Size, Share, Trends ...

Multiple System Atrophy (MSA) is a progressive, rare neurodegenerative disorder adversely affecting the autonomic nervous system, movement, balance, coordination, and various bodily functions.
The Globe and Mail

Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication ...

Multiple System Atrophy companies are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos ...
Yahoo Finance

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System ...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Seeking Alpha

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial ...

MELBOURNE, Australia and SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
Mena FN

Multiple System Atrophy Market In The 7MM Is Projected To Grow At A CAGR Of 50.60% By 2034 ...

DelveInsight's“ Multiple System Atrophy Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Multiple System Atrophy, historical and forecasted ...